Pharmaceuticals
Developers of branded and generic drugs. Value creation rests on R&D pipelines, patent lifecycles, regulatory approvals and pricing power versus payers.
| Unternehmen | Letzter Kurs | Kursänderung | Marktkapitalisierung | ||
|---|---|---|---|---|---|
|
|
|
Eli Lilly and Co
LLY
|
$1.159,185 |
-4,2%
|
$1,09 Bio. |
|
|
|
Johnson & Johnson
JNJ
|
$255,74 |
-3,7%
|
$615,62 Mrd. |
|
|
|
Roche Holding AG
ROG
|
CHf324,9 |
+4,1%
|
$326,70 Mrd. |
|
|
|
Merck & Co Inc
MRK
|
$129,965 |
-0,3%
|
$320,99 Mrd. |
|
|
|
Novartis AG
NOVN
|
CHf127,98 |
+0,9%
|
$303,43 Mrd. |
|
|
|
AstraZeneca PLC
AZN
|
12.822 |
-2,4%
|
$267,81 Mrd. |
|
|
|
Novo Nordisk A/S
NOVO B
|
kr330,9 |
0%
|
$225,71 Mrd. |
|
|
|
Pfizer Inc
PFE
|
$24,865 |
-1,1%
|
$141,72 Mrd. |
|
|
|
Nuvo Pharmaceuticals Inc
MRV
|
CA$26,58 |
-6,2%
|
$138,71 Mrd. |